A pilot study by OneSkin and academic collaborators evaluates the senomorphic peptide OS-01 in women aged 60–90. Over 12 weeks, researchers applied the peptide topically and monitored skin barrier function, transepidermal water loss, and systemic cytokine profiles via mass spectrometry. They observed localized peptide retention, reduced IL-8 levels, and notable improvements in hydration, elasticity, and appearance.

Key points

• OS-01, a senomorphic peptide, was topically applied to skin areas in 60 women aged 60–90.
• Mass spectrometry confirmed OS-01 remains localized, with no detectable systemic presence.
• Treated cohort exhibited significant reductions in pro-inflammatory cytokines IL-8 and balanced IL-10.
• Instrumental assays showed improved barrier function, increased moisture, and reduced transepidermal water loss.
• Participants reported enhanced skin elasticity, hydration, and visual appearance post-treatment.

Why it matters: Targeting skin senescence with a localized peptide that also lowers systemic inflammation suggests a novel therapeutic avenue for aging-related disorders. By modifying harmful cell signals rather than destroying cells, OS-01 may offer safer, more targeted interventions over existing senolytics, paving the way for broader applications in healthy aging.